Invesco Ltd. Raises Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Invesco Ltd. raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 6.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,790 shares of the company’s stock after buying an additional 2,010 shares during the quarter. Invesco Ltd.’s holdings in CRISPR Therapeutics were worth $1,330,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CRSP. ARK Investment Management LLC raised its stake in shares of CRISPR Therapeutics by 19.7% during the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock worth $353,180,000 after purchasing an additional 1,474,439 shares during the last quarter. Norges Bank purchased a new stake in shares of CRISPR Therapeutics during the fourth quarter worth approximately $17,458,000. Contrarius Group Holdings Ltd purchased a new stake in shares of CRISPR Therapeutics during the fourth quarter worth approximately $14,516,000. Raymond James Financial Inc. purchased a new stake in shares of CRISPR Therapeutics during the fourth quarter worth approximately $3,231,000. Finally, Van ECK Associates Corp raised its stake in shares of CRISPR Therapeutics by 5,269.3% during the fourth quarter. Van ECK Associates Corp now owns 83,010 shares of the company’s stock worth $3,267,000 after purchasing an additional 81,464 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares in the company, valued at $9,473,037.60. The trade was a 9.66 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Julianne Bruno sold 1,198 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the transaction, the chief operating officer now owns 8,263 shares in the company, valued at approximately $350,516.46. The trade was a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,381 shares of company stock valued at $1,608,243 over the last quarter. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Stock Up 3.4 %

CRSP opened at $38.67 on Thursday. The firm has a market cap of $3.34 billion, a P/E ratio of -8.85 and a beta of 1.85. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $67.88. The business’s fifty day simple moving average is $39.27 and its 200 day simple moving average is $43.36.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, equities analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Analyst Ratings Changes

CRSP has been the subject of several analyst reports. Evercore ISI upgraded CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and upped their price target for the stock from $60.00 to $99.00 in a research note on Friday, February 14th. HC Wainwright reiterated a “buy” rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Citigroup cut their price objective on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research report on Tuesday, February 18th. Royal Bank of Canada cut their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 12th. Finally, Bank of America cut their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Hold” and an average price target of $73.11.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.